Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Significant Decrease in Short Interest
Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) experienced a significant decrease in short interest, dropping 72.9% from 108,900 shares on April 30 to 29,500 shares by May 15. Currently, 0.0% of the company's shares are sold short, with a days-to-cover ratio of 0.1 days based on an average daily volume of 441,800 shares. The stock opened at $27.22, with a market cap of $51.94 billion and a P/E ratio of 31.65. Analysts forecast an EPS of 0.73 for the current fiscal year.
Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY - Get Free Report) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 29,500 shares, a decline of 72.9% from the April 30th total of 108,900 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 441,800 shares, the days-to-cover ratio is currently 0.1 days.
Get Daiichi Sankyo alerts:
Daiichi Sankyo Price Performance
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Daiichi Sankyo stock opened at $27.22 on Thursday. Daiichi Sankyo has a 52 week low of $20.92 and a 52 week high of $42.48. The business has a 50-day simple moving average of $24.33 and a 200 day simple moving average of $26.05. The company has a quick ratio of 2.11, a current ratio of 2.77 and a debt-to-equity ratio of 0.06. The stock has a market cap of $51.94 billion and a price-to-earnings ratio of 31.65.
Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last issued its quarterly earnings results on Friday, April 25th. The company reported $0.30 earnings per share (EPS) for the quarter. Daiichi Sankyo had a return on equity of 14.53% and a net margin of 13.62%. The firm had revenue of $3.40 billion during the quarter. On average, research analysts forecast that Daiichi Sankyo will post 0.73 earnings per share for the current fiscal year.
About Daiichi Sankyo
(Get Free Report)Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.
Featured Stories
- Five stocks we like better than Daiichi Sankyo
- What is a penny stock? A comprehensive guide
- AutoZone Stock to Cross $4400 This Year: This Is Why
- Stock Sentiment Analysis: How it Works
- Eli Lilly : A Breakout Biotech Powerhouse With Room to Run
- 3 Warren Buffett Stocks to Buy Now
- Top 5 Stock Buys for June: AI Picks That Aren’t NVIDIA
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Daiichi Sankyo Right Now?
Before you consider Daiichi Sankyo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daiichi Sankyo wasn't on the list.
While Daiichi Sankyo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here